The pilot program is temporary, and eligibility is based on BMI and other clinical criteria
The NLRP3 inflammasome is implicated in contrast-induced AKI by modulating the apoptotic pathway [209, 210]
Overall, the consequences are impairment of thyroid function, as measured by serum levels of thyroid hormones and/or TSH, and triggering of thyroid autoimmunity, as measured by serum levels of thyroid autoantibodies
[14] [15] Regular medication reviews typically every 36 months initially, then annuallyallow you and your healthcare team to reassess whether continuing GLP-1 therapy remains the best approach for your individual circumstances, based on both benefits and risks
For protocols that value regulatory-grade depth above all, tirzepatide remains the standard